BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Prior CEOs of Monsanto Company (MON) and Pfizer Inc. (PFE) Join Intrexon Corporation Board of Directors


11/28/2011 9:40:33 AM

BLACKSBURG, VA--(Marketwire - November 28, 2011) - Intrexon Corporation, a privately held synthetic biology engineering company, today announced the appointments of Robert B. Shapiro and Jeffrey B. Kindler to the Intrexon Board of Directors.

Mr. Shapiro brings extensive experience in the biochemical and biological sciences industry where he served as former Vice President, President, and CEO of Monsanto, in addition to serving as Chairman and CEO of the NutraSweet subsidiary of GD Searle & Company. He received a B.A. from Harvard University in 1959 and J.D. from Columbia University School of Law in 1962.

Mr. Kindler joins the Intrexon Board following his immediate past tenure as Chairman and CEO of Pfizer, Inc. Preceding his leadership of Pfizer, Mr. Kindler served as the Executive Vice President and General Counsel of McDonald's Corporation. He received a B.A. from Tufts University in 1977, followed by a J.D. magna cum laude from Harvard University in 1980.

Intrexon's Chairman and CEO Randal J. Kirk welcomes Mr. Shapiro and Mr. Kindler stating, "Intrexon has reached a strategic execution phase that will be greatly enhanced by guidance from Bob and Jeff. I am very pleased that executives of this caliber and experience have accepted our invitation and look forward to gaining the full benefit of their experience and insights."

About Intrexon Corporation
Intrexon Corporation is a privately held biotechnology company focused on the industrial engineering of synthetic biology. Intrexon is deploying its extensive engineering platform and capabilities to rapidly design and produce novel biofunctions and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company's advanced industrial engineering platform enables Better DNA™ technology by combining revolutionary DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. More information about the company is available at www.DNA.com.


Contact:
Andrew Udell
Intrexon Corporation
Phone: 301-556-9850
E-mail: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES